| pubmed-article:7285477 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7285477 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:7285477 | lifeskim:mentions | umls-concept:C0032912 | lld:lifeskim |
| pubmed-article:7285477 | lifeskim:mentions | umls-concept:C0022702 | lld:lifeskim |
| pubmed-article:7285477 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7285477 | pubmed:dateCreated | 1981-12-22 | lld:pubmed |
| pubmed-article:7285477 | pubmed:abstractText | Prazosin kinetics were studied after single doses (intravenous and oral, 0.5 mg) and after increasing multiple doses (0.5 to 5 mg three times daily) in eight patients with hypertension. After intravenous administration the kinetics could be described by a linear two-compartment open model. Terminal half-life (t1/2 beta) was about 3 hr and apparent volume of distribution (Vd beta) about 0.6 l/kg. After oral doses bioavailability ranged between 55% and 82%. Since total plasma clearance was low (0.14 l/kg x hr) incomplete bioavailability was the result of incomplete absorption rather than of first-pass liver metabolism. The estimated extraction ratio was about 14%. Renal clearance was negligible; only 1% to 2% of the dose was recovered unchanged in urine. Binding to plasma proteins to both albumin and alpha 1-acid glycoprotein was substantial (97%), with albumin being most important. Increasing multiple doses showed that prazosin followed first-order kinetics with a linear correlation between dose and steady-state plasma concentration (P less than 0.001). There were substantial variations in plasma concentrations between patients and there were also day-to-day variations in concentration within the same patient. | lld:pubmed |
| pubmed-article:7285477 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7285477 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7285477 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7285477 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7285477 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7285477 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7285477 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7285477 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:7285477 | pubmed:issn | 0009-9236 | lld:pubmed |
| pubmed-article:7285477 | pubmed:author | pubmed-author:HaglundKK | lld:pubmed |
| pubmed-article:7285477 | pubmed:author | pubmed-author:von BahrCC | lld:pubmed |
| pubmed-article:7285477 | pubmed:author | pubmed-author:LindströmBB | lld:pubmed |
| pubmed-article:7285477 | pubmed:author | pubmed-author:GrahnénAA | lld:pubmed |
| pubmed-article:7285477 | pubmed:author | pubmed-author:SeidemanPP | lld:pubmed |
| pubmed-article:7285477 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7285477 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:7285477 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7285477 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7285477 | pubmed:pagination | 439-46 | lld:pubmed |
| pubmed-article:7285477 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:meshHeading | pubmed-meshheading:7285477-... | lld:pubmed |
| pubmed-article:7285477 | pubmed:year | 1981 | lld:pubmed |
| pubmed-article:7285477 | pubmed:articleTitle | Prazosin kinetics in hypertension. | lld:pubmed |
| pubmed-article:7285477 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7285477 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7285477 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7285477 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7285477 | lld:pubmed |
